IN Brief:
- FDA proposes converting its voluntary GRAS notification programme into a mandatory system.
- The proposal covers human and animal food and substances added indirectly, including through food packaging.
- Comments are due by 9 December 2026 before FDA considers whether to issue a final rule.
The US Food and Drug Administration has proposed replacing its voluntary GRAS notification programme with a mandatory system for many substances used in human and animal food. The proposal would require companies introducing substances under the Generally Recognized as Safe provision to notify FDA of the basis for that conclusion unless an exception applies.
The distinction between notification and conventional food-additive approval is important. A substance that is GRAS under the conditions of its intended use remains outside the premarket approval requirement that applies to food additives. The proposed rule would instead require the company relying on the GRAS route to disclose the basis for its safety conclusion to FDA.
Under the current system, businesses may submit a GRAS notice but are not generally required to do so. FDA can therefore lack visibility of substances placed on the market on the basis of independent GRAS conclusions. The regulator says mandatory notification would give it more complete information about substances used in food and improve its ability to identify uses that may instead require food-additive approval.
The proposal covers substances used directly in human and animal food and substances added indirectly, including through food packaging. That gives the rule relevance beyond conventional ingredient suppliers, extending the compliance question into food-contact materials and other applications where a substance may enter food indirectly.
For manufacturers, the most immediate operational consequence would be documentation. Businesses relying on an independent GRAS conclusion would need to ensure that the scientific basis, intended conditions of use, supporting data, and other required information are organised for submission rather than held solely within internal files or by advisers.
That requirement could move regulatory work earlier in product development. A new ingredient or processing aid can affect formulation, sourcing, manufacturing trials, packaging, and commercial launch timing; if the GRAS basis must also be submitted, regulatory preparation becomes another workstream that has to be completed before the business can rely on the intended route to market.
The proposal includes exceptions and a time-limited streamlined submission option for certain uses of substances already introduced into interstate commerce before a final rule becomes effective. FDA is therefore not proposing that every historical use automatically go through the same full notice process on the same day, but companies would still need to determine whether their substances and intended uses qualify for an exception or the streamlined route.
The rule could be particularly significant for ingredient suppliers serving several applications. GRAS status is tied to the conditions of intended use, so a substance used across beverages, bakery, dairy, confectionery, prepared foods, or packaging cannot simply be treated as having one universal regulatory position regardless of concentration and application. Manufacturers and suppliers would need to map the intended uses on which their conclusions depend.
FDA is also proposing mandatory electronic submission of GRAS notices and requirements for English translations of supporting material. That has a direct implication for international ingredient companies selling into the US market, where scientific or manufacturing documentation may originally have been generated in another language or for a different regulatory system.
The agency’s preliminary economic analysis estimates annualised costs of about $10.5 million at a 3% discount rate over ten years, with a range from $4.1 million to $24.6 million. Costs include revising procedures, preparing notices, making streamlined submissions where applicable, and translating material. FDA also expects the proposal to have a significant economic impact on a substantial number of small entities.
Those estimates describe the regulatory burden across the affected market rather than the cost faced by an individual food manufacturer. The practical impact will vary according to how many substances a business introduces, whether it already uses the voluntary notification programme, how much supporting evidence is prepared in a submission-ready format, and whether it relies on independent GRAS conclusions for new applications.
For food manufacturers buying ingredients from third parties, the proposed rule could also change supplier qualification. A processor may need clearer evidence that the regulatory basis for an ingredient’s intended use has been addressed, particularly where a supplier previously relied on an internal GRAS conclusion. Regulatory status would therefore become more visible in commercial discussions between ingredient companies and their customers.
The proposal remains subject to public comment and is not yet a final compliance requirement. Comments are due by 9 December 2026, after which FDA can revise the text before deciding whether to issue a final rule and setting effective and compliance dates.
For the food industry, the direction of travel is nevertheless material. FDA is seeking to replace a voluntary disclosure route with mandatory notification while preserving the underlying distinction between GRAS uses and conventional food additives. If finalised, the change would make documentation and regulatory visibility a more explicit part of introducing substances into the US food supply, adding another formal control point to ingredient and packaging development.